Jasper Therapeutics to Present at Upcoming Investor Conferences in May [Yahoo! Finance]
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: Yahoo! Finance
development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May: Capital One Securities Biotech/Biopharma Disruptors Event Conference Dates: May 14, 2024 Presentation Date: Tuesday, May 14 at 2:45 p.m. EDT Presentation Format: Panel Discussion, “ New Dermatology Treatments ” 2024 RBC Capital Markets Global Healthcare Conference Conference Dates: May 14 – 15, 2024 Presentation Date: Wednesday, May 15 at 3:35 p.m. EDT Presentation Format: Fireside Chat A live webcast of the RBC Conference fireside chat will be available on the Events & News – Presentations page of Jasper's Investor Relations website. An archived replay of the fireside chat will be available on Jasper's website for 30 days following the live broadcast. About Jasper
Show less
Read more
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.MarketBeat
- Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments [Yahoo! Finance]Yahoo! Finance
- Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswire
- Jasper Therapeutics Announces Briquilimab Development Program in AsthmaGlobeNewswire
- Jasper Therapeutics to Present at Upcoming Investor Conferences in MayGlobeNewswire
JSPR
Earnings
- 5/14/24 - Beat
JSPR
Sec Filings
- 5/14/24 - Form 10-Q
- 5/3/24 - Form DEFA14A
- 4/22/24 - Form ARS
- JSPR's page on the SEC website